A block deal has been launched in pharmaceutical company Alkem Laboratories, according to sources.
The transaction involves the sale of up to a 1.5% stake in the company, with a base deal size of between ₹936 crore and ₹956 crore.
The floor price has been set at ₹5,200 per equity share, representing a discount of about 2.2% to the stock’s previous closing price of ₹5,314.50 per share.
Sources said the deal includes a 90-day lock-in on any further sale of shares by the seller.
Q4 results
Alkem Laboratories reported a 40.7% year-on-year rise in pre-exceptional profit to ₹557.8 crore in Q4FY26, aided by strong growth across domestic and international markets and improved operating leverage.
Revenue grew 14.6% to ₹3,603.3 crore, with domestic sales rising 8.8% to ₹2,324.5 crore and international business revenue increasing 25.4% to ₹1,222 crore. However, net profit after exceptional items fell 22.7% to ₹236.5 crore due to one-off charges of about ₹135 crore.
Shares of Alkem Laboratories ended lower on Monday, June 1, by 3.27% at ₹5,318 on the NSE.
ALSO READ | RBI clears Mirae Asset MF to raise stake in Equitas SFB up to 9.5%
(Edited by : Shoma Bhattacharjee)
